Clinical Trial Update: Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating subcutaneous immunotherapy for mite-induced allergic asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma

Drugs mentioned

• House dust mite subcutaneous immunotherapy (house dust mite extract immunotherapy)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Allergic Asthma | Phase 4 | Status: COMPLETED